Abstract
Methods A retrospective audit was undertaken of all EHAAT missions during 2013. All cases where the patient was classed as ‘positive’ by the Regional Major Trauma Network triage tool (MT+ve) were included. The primary outcome was the administration of the first bolus dose of 1g TXA (or paediatric appropriate dose). Compliance was defined as ‘patients thought to have significant haemorrhage received TXA’. Compliance with the local ambulance service guidelines (trauma patients with hypotension or tachycardia) was also reviewed.
Highlights
Essex and Herts Air Ambulance Trust (EHAAT) teams have carried tranexamic acid (TXA) on all missions since 2012
We have demonstrated that 100% of patients received TXA if attended by our service and thought to be significantly bleeding following trauma
We have demonstrated alignment with the local ambulance service guidelines pertaining to the use of TXA
Summary
Essex and Herts Air Ambulance Trust (EHAAT) teams have carried tranexamic acid (TXA) on all missions since 2012. Bleeding air ambulance patients: an audit of tranexamic acid use From London Trauma Conference 2014 London, UK. Background Essex and Herts Air Ambulance Trust (EHAAT) teams have carried tranexamic acid (TXA) on all missions since 2012. The CRASH-2 trial demonstrated a reduction in all-cause mortality in trauma patients thought to have significant haemorrhage.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
